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The application of molecnlar genetics to medicine is 
based on the observation that even common diseases 
have both genetic and environmental components. 
Conventional medicines are often effective in manag­
ing environmental components of disease but are gen­
erally ineffective in managing genetic diseases or ma­
nipulating the genetic component of multifactorial 
diseases. The development of therapies aimed at the 
genetic component of disease will require non-con­
ventional medicinal applications of molecular genet­
ics. Various approaches have been proposed such as 
diagnosing the propensity for disease to facilitate early 
intervention with conventional therapies, selectively 
eliminating mutant genes from human populations, 
correcting mutations in human chromosomes, and 
W e are in the midst of a revolution in biology and medicine. It is a revolution brought about by molecular biology, by the discovery of the structure of DNA and the deciphering of the genetic code, by the development of methods 
for recombination of genetic elements, and by the decision to pro­
ceed with sequencing the entire human genome. It is a revolution 
based on the postulate that by deciphering the genetic code, and 
learning how it contributes to both disease and the resistance to 
disease, medicine will acquire dramatic new healing powers. Scien­
tists, physicians, and the public share enormous expectations for a 
new age of genetic medicine, believing that the genetic understand­
ing of disease will make diseases such as cancer, morbid ageing, and 
infection amenable to efficacious medical management. 
The genetic approach to disease, however, is not new. The con­
cept that genetic inheritance contributes to both health and disease 
was expounded in detail by Sir Archibald Garrod, whose studies 
provided the first conclusive evidence for inherited disease in man. 
Garrod's landmark studies of Alkaptonuria, the first inborn error of 
metabolism to be recognized in humans, let him to consider the 
impact of genetics on human health and disease in general. Garrod's 
publication ofInborn Errors of Metabolism (1909) and Inborn Factors in 
Disease (1931) [1] outlined a surprisingly prescient view of human 
genetics. Garrod recognized that inherited disease was only the 
most manifest example of the role genetics played in human health 
and disease. He wrote (1931, p 157) 
It might be claimed that what used to be spoken of as a diathesis 
is nothing else but chemical individuality. But to our chemical 
individualities are due our chemical merits as well as our chemi­
cal shortcomings; and it is more nearly true to say that the 
factors which confer upon us our predispositions to, and im-
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using genes as medicines to modify the genetic compo­
nents of disease. of these, it is the development of gene 
medicines that has the greatest practical potential. The 
combination of conventional medicines, focused on 
the environmental components of disease, and gene 
medicines, focused on the genetic components, will 
provide the clinician with broad options for managing 
health and disease. The challenge to molecular biology 
is to develop gene medicines that are effective, safe, 
and socially acceptable. and therapies that map well to 
established clinical practice and may be employed ef­
ficaciously alongside conventional medicines. Key 
words: gene therapy/mutation diagnosis/genetic disease/ge­
netic screening.] Invest Dermatol103:2S-SS, 1994 
munities from the various mishaps which are spoken of as 
diseases, are inherent in our very chemical structure; and even 
in the molecular groupings which confer upon us our indivi­
dualities, and which went to the making of the chromosomes 
from which we sprang. 
Since the time of Garrod, the concept that both disease and the 
resistance to disease have a significant genetic component has been 
applied to many disorders that do not exhibit classical patterns of 
genetic inheritance. It is now generally accepted that there is a 
genetic component to diseases such as arthritis, cancer, and even 
dementia. In fact, the classical paradigm of allopathic medicine, in 
which disease is described as a perturbation of normal homeostatic 
mechanisms by exogenous, pathogenic agents, has been revised to 
reflect the understanding that most diseases can be described as 
having both genetic and environmental components. In this model, 
homeostasis is understood to involve a balance between inherent 
genetic functions in the patient and the environment. Perturbations 
in either genetically determined functions, or the environment in 
which they operate, can disturb this homeostasis resulting in dis­
ease. 
The relative genetic and environmental components underlying 
a series of dermatologic diseases are shown in Fig 1. In this repre­
sentation, the contribution of inherited factors is shown along the 
X-axis whereas the contribution of environmental factors is shown 
along the Y-axis. Certain diseases are almost entirely caused by 
environmental events, for example burns. On the other extreme, 
disorders such as congenital nevi are almost entirely caused by ge­
netic determinants.· Most conditions, however, can be graphed in 
the middle of this chart. Even inherited disorders such as epidermo­
lysis bullosa have an environmental component that is an essential 
·Genetic determinants may not be completely deterministic as evidenced 
by the stochastic component of many disorders as well as the phenomenon of 
incomplete penetrance or expressivity. 
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Figure 1. Genetic and environmental components of skin disease. 
part of the disease process. Skin pigmentation is clearly determined 
by genetic factors as well as environmental factors. The incidence of 
melanoma is related both to the inherited degree of skin pigmenta­
tion and environmental exposures. Disorders such as psoriasis and 
diabetes, for example, are profoundly affected by both genetic fac­
tors and environmental events. 
Garrod was perhaps the first to recognize that inherited diseases 
represented useful models in which to study the genetic contribu­
tion to disease in general. Since the original edition of Garrod's 
Inborn Errors of Metabolism in 1909, which listed four known inher­
ited metabolic diseases, almost 10,000 different inherited genetic 
disorders have been described. These have been catalogued by Vic­
tor McKusick [2]. Whereas considerable progress has been made in 
the understanding of genetic disease, less progress has been made in 
developing effective therapies using conventional medical ap­
proaches. 
CONVENTIONAL MEDICINE AND GENETIC DISEASE 
Conventional, allopathic medicine is focused on treating external, 
environmental components of disease. This approach is effective in 
dealing with disorders such as infections in which a discrete envi­
ronmental pathogen may be selectively eliminated. The conven­
tional approach to cancer similarly views cancer as an invading 
pathogen that can be attacked. The same conceptual approach is 
taken to diseases such as psoriasis in which invading immune cells or 
hyperproliferative epidermal cells are seen as pathogenic agents that 
can be eliminated by therapy. 
Conventional medicine, however, is not generally effective in 
treating genetic disease. The limitations of conventional medicine 
in treating genetic diseases were demonstrated in a study performed 
by Dr. Charles Scriver and Dr. Barton Childs and their colleagues at 
McGill University and The Johns Hopkins University [3,4]. These 
investigators studied a series of genetic disorders randomly selected 
from McKusick's catalog [2]. This study asked whether conven­
tional medicines (circa 1986) had a significant impact on the well­
being of patients with these disorders. They demonstrated that for 
greater than 70% of the diseases studied, conventional medicine had 
no significant effect on the well-being, longevity, appearance, 
schooling, or growth of afJIicted individuals. Thus, though there 
have been significant improvements in therapy for certain genetic 
diseases, these data suggested that there was something different 
about the nature of genetic disease that rendered these diseases less 
susceptible to conventional medicine. 
If genetic disease represents a model for the genetic component of 
multifactorial diseases, then it might be predicted that contempo­
rary medicines will not be as effective against the genetic compo­
nents of disease as they are against the environmental components. 
In considering the diseases shown in Fig 1 this appears to be true. 
Although there are efficacious therapeutic approaches to those dis­
eases having an extensive environmental component, those having a 
predominantly genetic origin are poorly addressed by conventional 
medicine, This is significant. If conventional medicines are gener­
ally ineffective against the genetic components of disease, then an 
improved understanding of the genetic origin of disease may not 
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necessarily lead to improved clinical therapies. Rather, novel ap­
proaches to treating disease may be required. The expectation is that 
these new approaches will arise from the application of molecular 
genetics to medical diagnosis and therapeutics. 
MOLECULAR GENETIC APPROACHES TO 
THERAPEUTICS 
Various strategies have been proposed for using molecular genetics 
to manage diseases with significant genetic components. It has been 
proposed that molecular diagnostics will be used to identify the 
propensity for disease before active pathogenesis is apparent, allow­
ing conventional medicines to be used to greater effect. It has been 
proposed that population screening might be used to eliminate dele­
terious genes from the population, therefore eliminating the risk of 
genetic disease. It has been proposed that genetic technologies 
might be used to correct the sequence of deleterious genes. Finally, 
it has been proposed that genes might be used as medicines to di­
rectly manipulate the genetic component of disease pathogenesis. 
Are these measures likely to be clinically feasible, efficacious, and 
acceptable? 
Diagnosing the Propensity for Disease The goal of the human 
genome project is not only to identify diseases caused by mutations 
in specific genes, but to identify the array of genetic elements in­
volved in common, multifactorial disease processes. Thus, whereas 
cancer is not caused by a singular mutation, various genetic elements 
are associated with the predisposition to cancer. Similarly, although 
inflammatory dermatitis is not caused by a discrete mutation, there 
are clearly several genetic elements that contribute to the disease. It 
is likely that as the genetic involvement in such diseases is increas­
ingly described on a molecular level, molecular genetics will allow 
diagnosis of those individuals who are at risk for these diseases. The 
expectation is that such diagnostic tests will alter medical practice by 
allowing physicians to recognize the propensity for disease rather 
than responding to its progression. The question, however, is 
whether this recognition will, in fact, lead to effective therapies. 
Clinical experience in managing cancer suggests that early diag­
nosis can have a significant impact on the outcome of disease. This 
benefit, however, arises not from actions taken to alter the genetic 
predisposition to disease, but from the application of medicinal and 
surgical therapies targeted to the environmental component of the 
disease. There are many examples of conventional therapies that 
alter the environment in such a way that multifactorial (genetic + 
environmental) diseases do not progress. For example, the treat­
ment of diabetes with diet, insulin, or oral hypoglycemic agents is 
an example of manipulating the environment to treat a disease that 
has a significant genetic component. So too, allergen avoidance for 
eczema and surgical removal of early melanomas represent effective 
therapies of diseases that are partially genetic. 
The effectiveness of therapy in this model, however, will not 
relate to the genetic component of disease, but to the extent that 
homeostasis can be restored in the presence of a genetic predisposi­
tion to disease by environmental manipulations. There is no reason 
to believe that improved diagnosis alone will enable conventional 
medicine to have a greater impact on the genetic component of 
multifactorial disease than it has on diseases that are largely genetic 
in nature. 
Eliminating Mutant Genes From Human Populations The 
concept of using molecular genetics to screen for treatable diseases 
must be clearly distinguished from the eugenic notion of screening 
for deleterious genes in the population so that these genes can be 
eliminated through prescriptive matings or selective abortion. Mea­
sures to limit the propagation of deleterious genes are still some­
times proposed as a means for eliminating genetic disease. More­
over, concern is often expressed that treating genetic disease could 
have the opposite effect, that by treating individuals with genetic 
(or partially genetic) diseases, the normal attrition of deleterious 
genes will be prevented and these genes will become increasingly 
prevalent in the population. 
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This line of reasoning represents the basis of eugenics as origi­
nally proposed by Francis Galton and the widespread application of 
social eugenic practices during the first half of this century. It is a 
line of reasoning that is scientifically invalid and prone to social 
abuse. It is invalid because the statistical effect of therapy on the 
gene pool for most multifactorial or even recessive diseases is likely 
to be extremely minor. Moreover, it assumes that we understand the 
complete medical impact of single genes within the human gene 
pool. In fact, we do not. There are estimated to be greater than 
100,000 genes in the human genome, and it has been estimated that 
everyone carries more than 5-10 genes that could be lethal if ex­
pressed in select genetic or environmental circumstances. We do 
not know, and perhaps cannot know with certainty, .the circum­
stances under which any single gene may induce dyshomeostasis. 
There are even examples of genes that are deleterious in one envi­
ronment, but beneficial effect in others such as Hb" which causes 
sickle cell disease but may also protect against malaria. Other dele­
terious genes may be closely linked to genes that are advantageous 
and thus propagate through the population together. Thus, it is 
virtually impossible to know whether elimination of specific genes 
through population screening would ultimately improve or impair 
the genome. 
This line of reasoning is prone to social abuse because the percep­
tion of whether a gene is deleterious reflects a social, cultural, and 
environmental context. Anthropologic studies teach that the signif­
icance of skin color, body habitus, and longevity varies profoundly 
in different human populations, in different regions of the world, 
and at different times in human cultural evolution. 
Finally, it is important to reiterate the ethical principles of fairness 
and individual freedom that make eugenic practices an anathema to 
modern society. Any practice that compromises the genetic freedom 
of the individual for social ends, no matter how apparently legiti­
mate the ultimate goal, may trespass down the slippery slope toward 
eugenics. Conversely, those applications of genetic technologies for 
preventing or treating genetic or acquired disease that preserve the 
principles of fairness, individual freedoms, and individual impera­
tives may not be eugenic in nature and may be acceptable to society 
[S].t 
Gene Correction Therapy It is commonly proposed that once 
mutations are identified in the genome, it will be possible to selec­
tively repair these mutations by genetic engineering. Methods for 
homologous recombination have been used to correct defects in 
inbred mouse lines leading to the perception that this pr()cedure 
may eventually be applicable in medical practice. It is not difficult to 
envision that bone marrow stem cells might be grown in the labora­
tory, that defects such a thalassemia, Hb, disease, or severe combined 
immunodeficiencies might be corrected in these cells, and that 
transplantation of these cells back into the host would lead to effec­
tive therapy. Current technologies, however, are not suitable for 
gene correction in large numbers of somatic cells. Current technol­
ogies provide little evidence that such methods might be feasible in 
the future. If, however, such methods were discovered, they might, 
in principle, be applicable in clinical practice . 
The potential for gene correction in embryonic cells raises both 
technical and ethical concerns. On the surface, this approach to 
eliminating genetic disease resembles medical therapeutics and 
seems less prone to eugenic abuse than measures to eliminate mutant 
genes by selective mating or abortion. There is concern, however, 
that while some mutations cause diseases that are obviously patho­
genic, gene correction, like eugenics, may be applied to more sub­
jective conditions that reflect social prejudice or power. As with 
population screening, the major concern relates to the potential loss 
of individual freedoms, and those therapies applied with due con­
cern for fairness and individual freedoms could be deemed accept­
able to society. 
t Ledley FD: Distinguishing genetics and eugenics on the basis of fairness 
(manuscript submitted). 
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There are, however, convincing logistic reasons to believe such 
therapy may not be applicable to medicine. Although gene correc­
tion in human embryos or embryonic stem cells in culture may 
prove to be technically feasible, the medical imperative to do no 
harm will remain predominant. Thus, the profound risks of genetic 
engineering of the germline must be compared to alternate ap­
proaches including preimplantation diagnosis or treatment of af­
fected individuals. It seems unlikely that gene correction will ever 
prove to be the procedure with the least potential for harm. 
Gene Medicines The potential for using genes as medicines to 
treat the genetic component of human disease arises from the iden­
tification and cloning of genes involved in various diseases as well as 
the ability to transfer genetic material into human cells. There are 
several ways in which gene medicines could be used in clinical 
therapeutics. Gene medicines can be used to replace expression of 
essential gene products in inherited disease. Gene medicines can be 
used to express gene products capable of restoring normal homeosta­
sis in the presence of multifactorial and environmentally induced 
disease. Finally, gene medicines may be used to re-engineer cells in 
the body making these cells less prone to disease or more sensitive to 
conventional medical therapeutics. 
Unlike conventional medicines, gene medicines will be directed 
explicitly at manipulating the genetic component of disease. The 
combination of conventional medicines, aimed at the environmen­
tal component of disease, and gene medicines, aimed at the genetic 
component of disease, may provide comprehensive therapeutic op­
portunities and could have an enormous impact on the management 
of health and disease. 
There has been extensive social debate on the use of genes in 
medical therapeutics. Despite sometimes rancorous debate, no gov­
ernment or religious body has objected to gene therapies as long as 
the genetic therapy is directed only at somatic cells and conven­
tional principles of balancing risk and benefit, obtaining voluntary 
informed consent, and adhering to the principles of fairness [6]. 
Because of the high visibility of gene therapy and level of social 
concern, a distinct review process has been established for gene 
therapy in which the Recombinant DNA Advisory Committee, 
acting in an advisory role to the Director of the NIH, performs a 
public review of all gene therapy applications in addition to the 
review performed by the FDA. To date, over 40 protocols for ex­
perimental gene therapy in human subjects have been proposed and 
approved. It is likely that within the decade hundreds of potential 
therapies will be proposed and that the first commercial products for 
gene therapy will be approved. The challenge is to derive clinically 
efficacious and acceptable gene medicines from the promise and the 
power of molecular genetics. . 
FROM GENES TO GENE MEDICINES 
The combination of conventional medicines and gene medicines 
promises to provide physicians with broad instruments for manag­
ing health and disease. Thus, gene medicines need to be developed 
that can be used in clinical practice in conjunction with conven­
tional medicines. Gene medicines will need to be administered by 
conventional routes of drug administration. They will need to pro­
vide a predictable therapeutic effect and appropriate duration of 
action. They will need to be acceptable to physicians and patients 
and to provide a balance of risk and benefit appropriate for each 
disease. Gene medicines need to be developed with the understand­
ing that they will be prescribed in routine clinical practice where 
diagnoses is often incorrect, where compliance is poor, where pa­
tients have concurrent diseases, where patients often take multiple 
medications simultaneously, where adverse experiences are often 
inexplicable, and where the cost of health care is an increasingly 
important factor in the selection among alternate therapies. 
These perspectives are essential in identifying appropriate meth­
ods and strategies for gene therapy. The ideal gene medicine for 
clinical application will be one that can be administered like a con­
ventional medicine to express therapeutic levels of the gene product 
at a specific site in the body for a finite period of time. Ideally, gene 
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delivery can be achieved using non-immunogenic materials to avoid 
the potential for interactions with other gene therapies, infections, 
or vaccines. Ideally too, genes will not incorporate into the genome 
of the host cell, but can be engineered to persist for a discrete, 
controlled period of time in an episomal state. This will eliminate 
any risk from insertional mutagenesis, allow the therapy to be 
stopped if adverse experiences are encountered. and provide a means 
for controlling the level of the gene product by adjusting the dose 
and schedule of administration. Although this picture of a gene 
medicine may differ from the theoretical ideal of a one shot cure for 
genetic disease, this picture embodies the attributes that will make 
such medicines useful in clinical practice. 
CONCLUSION 
Molecular genetics holds considerable therapeutic promise. The 
realization of this promise, however, requires critical analysis not 
only of the technical potential of molecular genetics, but how this 
potential maps to clinical practice. Ultimately it is not the elegance 
of the genetic approach to disease that will find acceptance in clini­
cal practice, but simply the development of therapeutic strategies 
and products that are effective, safe, facilitate compliance, and are 
cost effective. The development of gene medicines that may be used 
in conjunction with conventional medicines to deal with the ge-
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netic as well as environmental causes of disease will provide the 
physician with new and powerful therapeutic options for many 
common diseases. It is this approach that will allow patients and 
society to realize the therapeutic promise of molecular genetics. 
I would like to thank Dr. Charles Scriver for insighiful discussions concerning the 
concept oj genetic homeostasis. 
This work is SlIpporteJ in part by the ACTA FouruUtion and the Mather's 
Foundation. Dr. LeJley is a founder with equity interest in GBNBMBoICINE, INC. 
REFERENCES 
1. Garrod AE: Inbom Factors in Disease. In: Scriver CR, Childs B (eds.). Gtomd's 
Inborn Factors in Distdse. Oxford Univcmty Press. New York, 1989, pp 246 
2. McKusiclt V: Men,witln Inherirana in Man. Johns Hopkins Univcnity Press, Balti­
more, 1989 
3. Costa T. Scriver CR. Childs B: The effect of Mendelian disease on human health: a 
measurement. Am] Med Genet 21:231-242.1985 
4. Hayes A. Costa T, Scriver CR, Childs B: The effect of Mendelian disease on human 
health ll: respouae to treatment. Am] Mttl Genet 21:243-255.1985 
5. Ledley FD: Somatic gene therapy for human disease: a problem of eugenics? Tmuls 
Genet 3:112-115.1987 
6. Ledley FD: Are comcmporary methods for somatic gene therapy suitable for clini­
cal applications? elin Invest Mid 16:78-88. 1993 
